Original Research Article Iran J Med Microbiol. 2025; 19(6): 432-439

Category: Microbial Genetics Peer Reviewed | Open Access

10.22034/ijmm.19.6.432

Iranian Journal of Medical Microbiology | ISSN:2345-4342

Halotolerant *Bacillus licheniformis* Extract Induces Apoptosis in MCF-7 Cells via Modulation of BAX/BCL-2 Expression

Mahdiyeh Khoshandam[1], Mehrdad Memarian[2], Naser Kalhor[3], Mohadeseh Khoshandam[4], Hossein Soltaninejad[5*], Mohammad Taghi Hedayati Goudarzi[6]

1. *Department of Genetics, Islamic Azad University, Qom, Iran*
2. *Department of Microbiology, Islamic Azad University, Qom Branch, Qom, Iran*
3. *Department of Cell Biology and Regenerative Medicine, Academic Center for Education, Culture and Research, Qom Branch, Qom, Iran*
4. *National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran*
5. *Department of Stem Cells Technology and Tissue Regeneration, Faculty of Interdisciplinary Science and Technologies, Tarbiat Modares University, Tehran, Iran*
6. *Department of Cardiology, School of Medicine, Babol University of Medical Sciences, Babol, Iran*

ABSTRACT

Background and Aim: Breast cancer is one of the leading causes of cancer-related deaths among women worldwide. The resistance of advanced tumors to conventional treatments highlights the need for alternative therapies. Apoptosis, regulated by key proteins like BAX (pro-apoptotic) and BCL-2 (anti-apoptotic), plays a crucial role in controlling cancer cell proliferation. This study aimed to investigate the effects of a halotolerant *Bacillus (B.) licheniformis* extract, isolated from Hoz-e Sultan Lake in Qom Province, on the expression of *BAX* and *BCL-2* genes in MCF-7 breast cancer cell line.

Materials and Methods: MCF-7 cells were treated with various concentrations of the bacterial extract and cell viability was assessed using MTT assay. Staurosporine was used as positive control. RNA extraction, cDNA synthesis, and Real-Time PCR were performed to evaluate target genes expression levels. Statistical analysis was conducted using an independent t-test and P-values less than 0.05 were considered significant.

Results: The extract significantly increased *BAX* expression ($P<0.05$) at 24, 48, and 72 hr, while *BCL-2* expression initially decreased but showed a slight increase at 48 hr. The IC_{50} values decreased over time, indicating time-dependent cytotoxicity.

Conclusion: The halotolerant *B. licheniformis* extract induced apoptosis in MCF-7 cells through BAX/BCL-2 pathway modulation, suggesting its potential as an alternative therapeutic source. Further studies are needed to identify active compounds and validate efficacy *in vivo*.

Keywords: Apoptosis, *Bacillus licheniformis*, BAX, BCL-2, Breast Cancer, MCF-7

Received: 2025/10/15; **Accepted**: 2025/12/12; **Published Online:** 2025/12/29;

Corresponding Information: **Hossein Soltaninejad**, *Department of Stem Cells Technology and Tissue Regeneration, Faculty of Interdisciplinary Science and Technologies, Tarbiat Modares University, Tehran, Iran* & Email: Hossein.soltani@modares.ac.ir

1. Introduction

Breast cancer remains one of the most prevalent malignancies among women worldwide, accounting for a significant portion of cancer-related mortality **(1-3)**. Despite advancements in conventional treatments such as chemotherapy, radiotherapy, and hormone therapy, the emergence of drug resistance and recurrence underscores the urgent need for alternative therapeutic strategies **(4, 5)**. Apoptosis is a tightly regulated programmed cell death process that keeps up cellular homeostasis **(6, 7)**. Dysregulation of this pathway is a hallmark of cancer, allowing malignant cells to evade death **(8)**.

The BCL-2 protein family plays a pivotal role in this balance, where BAX promotes apoptosis, while BCL-2 acts as an anti-apoptotic regulator **(9)**. An increased BCL-2/BAX ratio has been frequently observed in breast cancer cells, contributing to their survival and resistance to therapy **(10, 11)**.

Halotolerant microorganisms from extreme environments have gained attention for their unique metabolic profiles and potential therapeutic applications **(12)**. Bacterial metabolites have recently gained attention for their anticancer potential, exhibiting cytotoxicity and immune modulation effects **(13, 14)**. Among them, *Bacillus (B.) licheniformis*, a spore-forming, Gram-positive bacterium commonly found in soil, has shown promising bioactive properties **(15, 16)**. The optimum growth temperature for *B. licheniformis* is approximately 50°C, though it can survive at much higher temperatures **(17)**. The ideal temperature for enzyme secretion is 37°C **(18)**. *B. licheniformis* can exist as resting spores, which can endure extreme environments and tolerate various nutritional conditions when favorable **(19)**.

However, its potential role in modulating apoptosis-related genes in breast cancer cells remains largely unexplored. This study aimed to evaluate the effects of a halotolerant *B. licheniformis* extract from the extreme environment of Hoz-e Sultan Lake on BAX and BCL-2 expression at both transcriptional and translational levels in MCF-7 cells.

2. Materials and Methods

2.1 Bacterial Source and Extract Preparation

B. licheniformis strain LZBL-3 was isolated from Hoz-e Sultan Lake in Qom Province, Iran. Its extract was used on MCF-7 breast cancer cells. *B. licheniformis* strain *LZBL-3* was cultured in LB broth medium for 48 hr at 35°C. After multiplication, the culture was subjected to centrifugation at 1,500 × g for 10 min at 4°C. The liquid upper part was taken and passed through a 0.22 µm membrane filter (Millipore, USA) in order to get a cell-free extract.

2.2 Cell Culture

MCF-7 cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin at a temperature of 37°C in a 5% CO_2 incubator. Untreated cells were utilized as the control group.

2.3 Cytotoxicity and IC50 Determination

The cytotoxic effect of the bacterial extract was evaluated using MTT assay (Sigma-Aldrich, USA). Cells were seeded in 96-well plates (1×10^4 cells/well) and treated with various extract concentrations (0.5 to 5 mg/mL) for 24, 48, and 72 hr. The absorbance was measured at 570 nm using a BioTek microplate reader. The inhibitory concentrations 50% (IC_{50}) values were calculated using nonlinear regression in GraphPad Prism 9.0.

2.4 RNA Extraction, cDNA Synthesis, and Real-Time PCR

RNA was extracted using TRIzol reagent (Invitrogen, USA), and cDNA synthesis was performed with the RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, USA) (20). Gene-specific primers (Table 1) were designed using NCBI Primer-BLAST. Real-Time PCR was conducted using SYBR Green Master Mix (Applied Biosystems, USA). GAPDH was used as the reference gene. Relative gene expression for *BAX* and *BCL-2* genes were calculated using the 2^−ΔΔCt method **(21)**.

2.5 Statistical Analysis

Statistical analyses were performed using IBM SPSS version 22 (IBM, USA) and REST 2009 software. Data are presented as mean ± standard deviation (SD) from three independent tests. All experiments were performed using three independent biological replicates (n = 3), each derived from separate cell cultures conducted on different days. These experiments were subsequently expanded to include a comparison in Tokyo and for multiple comparisons ANOVA for further analysis. Statistical differences between groups were analyzed using an independent t-test, and a P-value less than 0.05 was considered statistically significant.

Table 1. PRISMA flowchart demonstrating literature search and selection process 126.

Accession Number	Genes	Forward Primer (5'→3')	Reverse Primer (5'→3')	Product Size (bp)	Reference
NM_001289746.2	*GAPDH*	GATGTTCTGGAGAGCCCC	GCCCAATACGACCAAATCC	93	Khoshandam et al **(21)**
NM_004324.4	*BAX*	CAGTTGAAGTTGCCGTCAG	AGTCTCACCCAACCACCC	150	
NM_000633.3	*BCL-2*	TGCATATTTGTTTGGGGCAG	CGTACAGTTCCACAAAGGCA	87	

3. Results

3.1 Cell Viability and IC_{50} Determination

The bacterial extract exhibited dose- and time-dependent cytotoxicity. The IC_{50} values decreased from 4.3 mg/mL at 24 hr to 2.1 mg/mL at 72 hr (Figure 1).

3.2 Gene Expression Analysis Results

The expression levels of *BAX* gene in the treatment group significantly increased over 24, 48, and 72 hr compared to the control group. In contrast, the expression level of *BCL-2* gene in the treatment group decreased after 24 hr compared to the control group. however, this decrease was not statistically significant. Additionally, the expression level of *BCL-2* gene in the treatment group increased compared to the control group over 48 and 72-hrperiods, and this increase was found to be significant (Figure 2).

3.3 Melting Curve

The melting curves obtained from the amplification of the studied genes are shown in Figure 3, which indicates the specific performance of the desired reaction.



Figure 1. Molecular weight of bacteriocins produced by *Bacillus paramycoides* strain SDS-PAGE **(Prepared by Authors, 2025)**.



Figure 2. Molecular weight of bacteriocins produced by *Bacillus paramycoides* strain SDS-PAGE **(Prepared by Authors, 2025)**.



Figure 3. Molecular weight of bacteriocins produced by *Bacillus paramycoides* strain SDS-PAGE **(Prepared by Authors, 2025)**.

4. Discussion

Apoptosis is a type of genetically programmed cell death that has a vital function in various physiological and pathological conditions and acts like a double-edged sword **(2, 6)**. BAX protein serves as a key component in apoptosis, particularly in the intrinsic apoptotic pathway, while BCL-2 protein exerts an anti-apoptotic effect in response to various apoptotic stimuli by preventing the release of cytochrome *C* from the mitochondria **(22)**. Both BAX and BCL-2 are

critical players in the mitochondrial pathway of apoptosis **(23)**.

In cancer cells, the balance between proliferation and apoptosis is often disrupted, necessitating the inhibition of apoptosis for excessive growth and proliferation **(24, 25)**. This disruption creates a direct link between the expression of these genes and the process of carcinogenesis **(26, 27)**. Therefore, investigating the effects of new drugs on the expression of these genes could enhance our understanding of therapeutic and diagnostic strategies in cancer research **(28, 29)**.

A study conducted in 2020 further suggested that *BCL-2* gene is integral to the progression of breast cancer **(30)**. It has been noted that *BCL-2* gene expression is increased in various cancer types, and the product of this gene plays a role in promoting growth and survival while inhibiting programmed cell death **(10, 31)**. In 2022, researchers examining the role of BCL-2 family proteins in the regulation of apoptosis and cancer treatment concluded that these proteins are crucial regulators of apoptosis, significantly influencing tumorigenesis, development, and therapeutic responses **(9)**. Inhibition of apoptosis by members of the BCL-2 family is often observed at elevated levels in human tumor tissues, which contributes to the prevention of apoptosis in tumor cells **(32)**. In this context, inhibition of BCL-2 may re-enable apoptosis in these cells **(33)**. Consequently, effective and targeted antitumor drugs could be developed for the treatment of malignant tumors by either activating the expression of anti-apoptotic proteins or by promoting the expression of pro-apoptotic proteins **(34)**. Overall, these findings underscore the potential of BcL-2 family proteins in cancer treatment **(23)**.

Our findings demonstrated that *Bacillus licheniformis* extract significantly upregulated *BAX* expression at all time points, promoting apoptotic pathways in MCF-7 cells. Conversely, *BCL-2* expression showed an initial decrease at 24 hr, followed by a surprising increase at 48 and 72 hr. This biphasic response suggests a dynamic interaction between pro-apoptotic and anti-apoptotic mechanisms. These results align with previous studies indicating that bacterial metabolites can induce apoptosis by targeting mitochondrial pathways **(35-37)**. The significant upregulation of *BAX* supports the hypothesis that *Bacillus licheniformis* triggers intrinsic apoptosis, consistent with findings from *Lactiplantibacillus plantarum* extracts, which similarly enhanced *BAX* expression while downregulating *BCL-2* in breast cancer models **(38)**. The observed resurgence of *BCL-2* expression at 48 and 72 hr may reflect an adaptive resistance mechanism. Studies have reported similar delayed *BCL-2* upregulation in response to apoptotic stress, potentially mediated by PI3K/AKT or NF-κB survival pathways **(39)**.

This highlights the need for combination therapies that simultaneously target pro-survival signaling to prevent late-stage resistance. The research outcomes serve as initial *in vitro* proof that *Bacillus licheniformis* extract is capable of altering the expression of genes linked to apoptosis in breast cancer cells. Nonetheless, more *in vivo* and clinical studies are necessary to confirm its therapeutic potential. Future research should focus on *in vivo* validation and proteomic analysis to uncover the secondary metabolites responsible for apoptosis induction. Additionally, the biphasic response of *BCL-2* expression highlights the importance of further studies to assess whether modulation of apoptotic pathways by bacterial extracts could affect cellular responses to other apoptosis-targeting interventions.

5. Conclusion

Our findings support the growing evidence that bacterial extracts, particularly *Bacillus licheniformis* represents a biologically active microbial source that modulates apoptosis-related gene expression in breast cancer cells under *in vitro* conditions. Further *in vivo* validation and mechanistic investigations are required to clarify the translational relevance of these findings. Moreover, combination strategies with BCL-2 inhibitors may enhance the therapeutic efficacy and prevent late-stage cancer cell adaptation, a key challenge in breast cancer therapy.

6. Declarations

6.1 Acknowledgment

This research was conducted in collaboration with the Research ACECR of Qom University Jihad.

6.2 Ethical Considerations

This study did not involve human participants or animals.

6.3 Authors' Contributions

All authors participated in the design, execution, and writing of the article equally.. All participants agreed to be involved in this study. All authors read and approved the final version.

6.4 Conflict of Interests

The authors declare that they have no known competing financial interests or personal relationships

that could have influenced the work reported in this paper.

6.5 Financial Support and Sponsorship

This study received no financial support.

6.6 Using Artificial Intelligence Tools (AI Tools)

ChatGPT was used only for grammar and syntax correction only. The authors reviewed and take responsibility for the final content.

References

1. Kim J, Harper A, McCormack V, Sung H, Houssami N, Morgan E, et al. Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nat Med. 2025;31(4):1154-62. [PMID] [DOI:10.1038/s41591-024-02887-x] [DOI:10.1038/s41591-025-03502-3]
2. Khoshandam M, Soheili ZS, Hosseinkhani S, Samiee S, Latifi-Navid H, Ahmadieh H, et al. In vivo inhibition of angiogenesis by htsFLT01/MiRGD nano complex. Transl Oncol. 2025;56:102400. [PMID] [PMCID] [DOI:10.1016/j.tranon.2025.102400]
3. Farhangfar SD, Fesahat F, Zare-Zardini H, Dehghan-Manshadi M, Zare F, Miresmaeili SM, et al. In vivo study of anticancer activity of ginsenoside Rh2-containing arginine-reduced graphene in a mouse model of breast cancer. Iran J Basic Med Sci. 2022;25(12):1442.
4. Riaz N, Jeen T, Whelan TJ, Nielsen TO. Recent advances in optimizing radiation therapy decisions in early invasive breast cancer. Cancers. 2023;15(4):1260. [PMID] [PMCID] [DOI:10.3390/cancers15041260]
5. Obeagu EI, Obeagu GU. Breast cancer: A review of risk factors and diagnosis. Medicine. 2024; 103(3):e36905. [PMID] [PMCID] [DOI:10.1097/MD.0000000000036905]
6. Yuan, J. and D. Ofengeim, A guide to cell death pathways. Nat Rev Mol Cell Biol. 2024;25(5): 379-95. [DOI:10.1038/s41580-023-00689-6] [PMID]
7. Fath-Bayati L, Naserpour L, Khoshandam M, Jannatifar R, Fazaeli H. Recent advances in developing 3D culture systems of spermatogonial stem cell preservation and differentiation: A narrative review. Int J Reprod BioMed. 2023;21(9):681. [PMID] [PMCID] [DOI:10.18502/ijrm.v21i9.14397]
8. Dandoti S. Mechanisms adopted by cancer cells to escape apoptosis-A review. Biocell. 2021; 45(4):863. [DOI:10.32604/biocell.2021.013993]
9. Qian S, Wei Z, Yang W, Huang J, Yang Y, Wang J. The role of BCL-2 family proteins in regulating apoptosis and cancer therapy. Front Oncol. 2022;12:985363. [PMID] [PMCID] [DOI:10.3389/fonc.2022.985363]
10. Iksen, Witayateeraporn W, Hardianti B, Pongrakhananon V. Comprehensive review of Bcl-2 family proteins in cancer apoptosis: Therapeutic strategies and promising updates of natural bioactive compounds and small molecules. Phytother Res. 2024;38(5):2249-75. [DOI:10.1002/ptr.8157] [PMID]
11. Bahadar N, Bahadar S, Sajid A, Wahid M, Ali G, Alghamdi A, et al. Epigallocatechin gallate and curcumin inhibit Bcl-2: a pharmacophore and docking based approach against cancer. Breast Cancer Res. 2024;26(1):114. [PMID] [PMCID] [DOI:10.1186/s13058-024-01868-9]
12. Zeigler DR, Perkins JB. The genus bacillus. InPractical handbook of microbiology. 2021 May 4 (pp. 249-278). CRC Press. [DOI:10.1201/9781003099277-24]
13. Lu S, Wang C, Ma J, Wang Y. Metabolic mediators: microbial-derived metabolites as key regulators of anti-tumor immunity, immunotherapy, and chemotherapy. Front Immunol. 2024;15:1456030. [PMID] [PMCID] [DOI:10.3389/fimmu.2024.1456030]
14. Giurini EF, Godla A, Gupta KH. Redefining bioactive small molecules from microbial metabolites as revolutionary anticancer agents. Cancer Gene Ther. 2024;31(2):187-206. [PMID] [DOI:10.1038/s41417-023-00715-x] [PMCID]
15. Shleeva MO, Kondratieva DA, Kaprelyants AS. Bacillus licheniformis: a producer of antimicrobial substances, including antimycobacterials, which are feasible for medical applications. Pharmaceutics. 2023; 15(7):1893. [PMID] [PMCID] [DOI:10.3390/pharmaceutics15071893]
16. Ramirez-Olea H, Reyes-Ballesteros B, Chavez-Santoscoy RA. Potential application of the probiotic Bacillus licheniformis as an adjuvant in

the treatment of diseases in humans and animals: A systematic review. Front Microbiol. 2022;13:993451. [PMID] [PMCID] [DOI:10.3389/fmicb.2022.993451]

17. Evelyn, Utami SP, Chairul. Effect of temperature and soluble solid on Bacillus subtilis and Bacillus licheniformis spore inactivation and quality degradation of pineapple juice. Food Sci Technol Int. 2022;28(4):285-96. [DOI:10.1177/10820132211019143] [PMID]
18. Espoui AH, Larimi SG, Darzi GN. Optimization of protease production process using bran waste using Bacillus licheniformis. Korean J Chem Eng. 2022;39(3):674-83. [DOI:10.1007/s11814-021-0965-3]
19. Li C, Liu Z, Zhao J, Zhao ZM. Mechanisms and strategies for regulating sporulation and germination of Bacillus subtilis to enhance probiotic effects. Ind Crops Prod. 2024;220: 119178. [DOI:10.1016/j.indcrop.2024.119178]
20. Khodadoost M, Khoshandam M, Mirtorabi SD, Ghadirzadeh MR, Ahangari G. Gene Expression Survey of Serotonin Receptors (5HTR2A and 5HTR3A) and Monoamine Oxidases Enzyme After Treatment With Methadone in Addicted Individuals. Int J Med Toxicol Forensic Med. 2019;9(3):125-32. [DOI:10.32598/ijmtfm.v9i3.25480]
21. Khoshandam M, Soheili ZS, Hosseinkhani S, Samiee S, Latifi-Navid H, Kalhor N, et al. Leveraging the htsFLT01/MiRGD Complex to Enhance Apoptosis and Suppress Angiogenesis in MCF7 Breast Cancer Cells. Iran J Med Sci. 2025;50(10):707.
22. Mustafa M, Ahmad R, Tantry IQ, Ahmad W, Siddiqui S, Alam M, et al. Apoptosis: a comprehensive overview of signaling pathways, morphological changes, and physiological significance and therapeutic implications. Cells. 2024;13(22):1838. [DOI:10.3390/cells13221838] [PMID] [PMCID]
23. Saddam M, Paul SK, Habib MA, Fahim MA, Mimi A, Islam S, et al. Emerging biomarkers and potential therapeutics of the BCL-2 protein family: the apoptotic and anti-apoptotic context. Egypt J Med Hum Genet. 2024;25(1): 12. [DOI:10.1186/s43042-024-00485-7]
24. Loftus LV, Amend SR, Pienta KJ. Interplay between cell death and cell proliferation reveals new strategies for cancer therapy. Int J Mol Sci. 2022;23(9):4723. [DOI:10.3390/ijms23094723] [PMID] [PMCID]
25. Khoshandam M, Naserpour L, Goudarzi MT, Soltaninejad H, Zare-Zardini H, Hoseiny AA, et al. Regulatory Roles of MicroRNAs in Female and Male Human Reproduction: A Narrative Review. Iran J Med Sci. 2025;50(9):588.
26. Jia LT, Chen SY, Yang AG. Cancer gene therapy targeting cellular apoptosis machinery. Cancer Treat Rev. 2012;38(7):868-76. [DOI:10.1016/j.ctrv.2012.06.008] [PMID]
27. Jabbari K, Khalafizadeh A, Sheikhbahaei M, Soltaninejad H, Babashah S. TET1: the epigenetic architect of clinical disease progression. Genes Dis. 2025;12(5):101513. [DOI:10.1016/j.gendis.2025.101513] [PMID] [PMCID]
28. Zaimy MA, Saffarzadeh N, Mohammadi A, Pourghadamyari H, Izadi P, Sarli A, et al. New methods in the diagnosis of cancer and gene therapy of cancer based on nanoparticles. Cancer Gene Ther. 2017;24(6):233-43. [DOI:10.1038/cgt.2017.16] [PMID]
29. Yang P, Khoshandam M, Bhia I, Raji S, Soltaninejad H, Hosseinkhani S, et al. Integrating CRISPR/Cas technology with clinical trials: principles, progress, and challenges. Asian J Pharm Sci. 2025:101068. [PMCID] [DOI:10.1016/j.ajps.2025.101068] [PMID]
30. Hwang KT, Kim YA, Kim J, Oh HJ, Park JH, Choi IS, et al. Prognostic influences of BCL1 and BCL2 expression on disease-free survival in breast cancer. Sci Rep. 2021;11(1):11942. [PMCID] [DOI:10.1038/s41598-021-90506-x] [PMID]
31. Placzek WJ, Wei J, Kitada S, Zhai D, Reed JC, Pellecchia M. A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy. Cell Death Dis. 2010;1(5):e40. [DOI:10.1038/cddis.2010.18] [PMID] [PMCID]
32. Markouli M, Pagoni MN, Diamantopoulos P. BCL-2 inhibitors in hematological malignancies: biomarkers that predict response and management strategies. Front Oncol. 2025;14: 1501950. [DOI:10.3389/fonc.2024.1501950] [PMID] [PMCID]
33. Zhang L, Lu Z, Zhao X. Targeting Bcl-2 for cancer therapy. Biochim Biophys Acta Rev Cancer. 2021;1876(1):188569. [PMID] [PMCID] [DOI:10.1016/j.bbcan.2021.188569]
34. Chaudhry GE, Akim AM, Sung YY, Muhammad TS. Cancer and apoptosis. InApoptosis and cancer: methods and protocols 2022 Sep 11

(pp. 191-210). New York, NY: Springer US. [DOI:10.1007/978-1-0716-2553-8_16] [PMID]

35. Altonsy MO, Andrews SC, Tuohy KM. Differential induction of apoptosis in human colonic carcinoma cells (Caco-2) by Atopobium, and commensal, probiotic and enteropathogenic bacteria: mediation by the mitochondrial pathway. Int J Food Microbiol. 2010;137(2-3):190-203. [PMID] [DOI:10.1016/j.ijfoodmicro.2009.11.015]

36. Lobet E, Letesson JJ, Arnould T. Mitochondria: a target for bacteria. Biochem Pharmacol. 2015; 94(3):173-85. [DOI:10.1016/j.bcp.2015.02.007] [PMID]

37. Kokoulin MS, Kuzmich AS, Filshtein AP, Prassolov VS, Romanenko LA. Capsular polysaccharide from the marine bacterium Cobetia marina induces apoptosis via both caspase-dependent and mitochondria-mediated pathways in HL-60 cells. Carbohydr Polym. 2025;347:122791. [DOI:10.1016/j.carbpol.2024.122791] [PMID]

38. Budu O, Mioc A, Soica C, Caruntu F, Milan A, Oprean C, et al. Lactiplantibacillus plantarum induces apoptosis in melanoma and breast cancer cells. Microorganisms. 2024;12(1):182. [DOI:10.3390/microorganisms12010182] [PMID] [PMCID]

39. Areewong S, Suppramote O, Prasopporn S, Jirawatnotai S. Exploiting acquired vulnerability to develop novel treatments for cholangiocarcinoma. Cancer Cell Int. 2024; 24(1):362. [DOI:10.1186/s12935-024-03548-2] [PMID] [PMCID]